Overview and Scope
A VEGF inhibitor is an inhibitor that prevents planned cell death by acting as
an anti-apoptotic factor for hematopoietic cells. VEGF increases vascular
permeability, which may make it easier for tumours to spread via the
bloodstream and receive more oxygen and nutrients.
Sizing and Forecast
The vascular endothelial growth factor (vegf) inhibitor market size has grown
strongly in recent years. It will grow from $9.68 billion in 2023 to $10.46
billion in 2024 at a compound annual growth rate (CAGR) of 8.0%. The
growth in the historic period can be attributed to increase in cancer
prevalence, strong economic growth in emerging markets, increase in
pharmaceutical r&d expenditure, increased healthcare expenditure,
government initiatives and rapid growth in elderly population.
The vascular endothelial growth factor (vegf) inhibitor market size is expected
to see strong growth in the next few years. It will grow to $13.98 billion in
2028 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be
attributed to increasing prevalence of cancer, rising prevalence of age-related
macular degeneration (amd), rise in healthcare expenditure, high potential of
emerging economies, high penetration of the biosimilar drugs and increasing
geriatric population. Major trends in the forecast period include offering
combination therapies to patients in order to combat advanced cancers and
improve patient life, focusing on strategic collaborations to boost innovations
and establish category leadership, investing extensively in r&d activities
for the development of effective and innovative drugs, focusing on the
production of biosimilars in order to cater to a wider market by making
treatment more affordable and focusing on reducing dosages for wet age-related
macular degeneration (amd) in order to improve patient welfare.
Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/vascular-endothelial-growth-factor-inhibitors-global-market-report
Segmentation & Regional Insights
The vascular endothelial growth factor (vegf) inhibitor market covered in this
report is segmented –
1) By Drugs Type: Avastin, Tecentriq, Lucentis, Tagrisso, Cometriq, Eylea,
Other Drug Types
2) By Route Of Administration: Oral, Intravenous, Intravitreal
3) By Application: Oncology, Ophthalmology, Other Applications
North America was the largest region in the vascular endothelial growth factor
(VEGF) inhibitor market in 2023. Middle East is expected to be the fastest-growing
region in the vascular endothelial growth factor (VEGF) inhibitor market share
during the forecast period. The regions covered in the vascular endothelial
growth factor (vegf) inhibitor market report are Asia-Pacific, Western Europe,
Eastern Europe, North America, South America, Middle East, Africa
Intrigued to explore the contents? Secure your hands-on a free sample copy of
the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3437&type=smp
Major Driver Impacting Market Growth
The growing prevalence of cancer and macular degeneration diseases is expected
to drive the VEGF inhibitor market. For instance, in August 2022, according to
this systematic review and meta-analysis published by the National Library of
Medicine, a US-based medical library, age-related macular degeneration will
affect 8–7% of the global population, with the illness affecting 196 million
individuals in 2020 and rising to 288 million by 2040. Anti-vascular
endothelial growth factor (anti-VEGF) agents halt the progression of the
disease and improve vision. A vascular endothelial growth factor (VEGF)
inhibitor slows and restricts tumor growth during cancers. Hence, the rising
prevalence of cancer along with macular degeneration disease aids in the
vascular endothelial growth factor (VEGF) inhibitor market growth over the
forecast period.
Key Industry Players
Major companies operating in the vascular endothelial growth factor (vegf)
inhibitor market report are F. Hoffmann-La Roche AG, Bayer AG, Regeneron
Pharmaceuticals Inc., Astrazeneca Plc., Novartis AG, Pfizer Inc., Eli Lilly and
Company, Exelixis Inc., Amgen Inc., Sanofi S.A., Cipla Limited, Biocon, Dr.
Reddy's Laboratories, Chi-Med, Innovent Biologics, Daiichi Sankyo, Chugai
Pharmaceutical Co. Ltd, AstraZeneca plc, Allergan plc., Boehringer Ingelheim
International GmbH, GlaxoSmithKline plc, Ipsen, Oxurion, AVEO Oncology,
Pharmstandard Group, Zentiva, Coherus BioSciences Inc., Celgene, Exelixis Inc.,
Regeneron Pharmaceuticals Inc., AVEO pharmaceuticals, Eisai Co. Ltd.
The vascular endothelial growth factor (vegf) inhibitor market report table of
contents includes:
1. Executive Summary
2. Vascular
Endothelial Growth Factor (VEGF) Inhibitor Market Characteristics
3. Vascular
Endothelial Growth Factor (VEGF) Inhibitor Market Trends And Strategies
4. Vascular
Endothelial Growth Factor (VEGF) Inhibitor Market - Macro Economic Scenario
5. Global
Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Size and Growth
.
32. Global
Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Competitive
Benchmarking
33. Global
Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Competitive
Dashboard
34. Key
Mergers And Acquisitions In The Vascular Endothelial Growth Factor (VEGF)
Inhibitor Market
35.
Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Future Outlook and
Potential Analysis
36.
Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model:
https://www.thebusinessresearchcompany.com/global-market-model
No comments:
Post a Comment